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Summary
The year 2011 was a breakthrough in melanoma treatment with two new targeted 
drugs, ipilimumab and vemurafenib, approved after showing overall survival benefit 
in patients with metastatic melanoma. Vemurafenib was approved only for treatment 
of patients with activating mutations in BRAF gene. Thus, the detection of activating 
BRAF mutations, which can be found in ≈50% melanomas, became a standard part 
of a routine protocol for the treatment of patients with metastatic melanoma. In this 
review, methods and protocols for the detection of BRAF mutations as an example of 
molecular marker for personalised approach to patients with melanoma are discussed, 
with an emphasis on the aspects that are still a matter of discussion and controversies. In 
addition to BRAF mutations, some other molecular markers for personalised approach 
to melanoma patients, such as predictive markers for ipilimumab therapy that are still 
not used routinely, are briefly discussed.
Keywords: melanoma; BRAF mutations; vemurafenib; ipilimumab; predictive mar-
kers; personalised medicine.
INTRODUCTION
Melanoma of the skin is the fifth most common cancer in the USA with 
the incidence rate of 21.3 per 100000 people per year [1]. The incidence of 
melanoma of the skin has been rising constantly with the average increase 
of 1.8% each year over 2002-2011 [1]. Unlike the incidence, the mortality was 
stable for the same period, the mortality rate being 2.7 per 100000 people per 
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year [1]. In the Republic of Croatia the incidence rate age-standardized to 
European Union population was 12.3 per 100000 in 2011 [2]. The discrepancy 
between incidence and mortality rate can be attributed to high survival rate 
for non-metastatic melanoma, the 5-year survival rate for localized melano-
ma being 98.1% [1]. However, the 5-year survival rate for melanoma patients 
with distant metastases is only 16.1% [1]. The poor outcome of patients with 
metastatic melanoma is mostly due to inefficient therapeutic options that 
were available until recently. The only two drugs approved and widely used 
for treating metastatic melanoma until 2011 were dacarbazine and interleu-
kin-2, but neither of them showed improved overall survival benefit [3]. 
TARGETED THERAPY FOR MELANOMA
In 2011, two targeted therapy drugs, ipilimumab and vemurafenib, were 
approved for the treatment of metastatic melanoma. Unlike dacarbazine and 
interleukin-2, both ipilimumab and vemurafenib have shown overall survi-
val benefit in patients with metastatic melanoma [4-6]. 
Ipilimumab, an immunotherapy drug, is a monoclonal antibody that tar-
gets immune checkpoint by binding specifically to cytotoxic T-lymphocyte 
antigen-4 (CTLA-4). CTLA-4 is an inhibitory receptor on T cells that binds 
CD80 and CD86 molecules on antigen-presenting cells during T-cell activa-
tion [7]. Blockade of CTLA-4 with specific antibodies like ipilimumab results 
with increased T cell activation and proliferation, and consequently with im-
proved immune response against melanoma antigens [7]. Approval of ipili-
mumab for the treatment of unresectable or metastatic melanoma by the U.S. 
Food and Drug Administration (FDA) in 2011 was based on phase III clinical 
trial in which previously treated metastatic melanoma patients treated with 
ipilimumab and glycoprotein 100 (gp100) vaccine had improved survival 
compared to patients treated only with gp100 vaccine [4]. In another phase 
III randomized trial on previously untreated metastatic melanoma patients, 
median overall survival was significantly longer in patients treated with ipi-
limumab and dacarbazine compared to patients treated with only dacarba-
zine (11.2 months vs 9.1 months) [5]. In these clinical trials only 10-15% of 
melanoma patients responded to ipilimumab according to response evalua-
tion criteria in solid tumors (RECIST) [4,5]. However, the response to ipilimu-
mab treatment is different from typical response to cytotoxic cancer drugs. 
In some patients disease progression or development of new metastatic le-
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sions was observed prior to ipilimumab induced disease control associated 
with improved survival [4,5,8]. Therefore different set of response criteria, 
immune-related response criteria (irRC), was developed as more appropriate 
to assess ipilimumab response compared to standard RECIST criteria [8]. The 
survival benefits in melanoma patients responding to ipilimumab seem to be 
long lasting. Pooled analysis of long-term survival data from different ipili-
mumab clinical trials has shown 22% three-year overall survival rate with 
survival curve reaching plateau around 3 years that extends through at least 
10 years [9]. In clinical trials ipilimumab treatment was associated with more 
frequent and sometimes severe toxicities, notably specific immune-related 
adverse events [4,5]. Other targeted immunotherapy drugs have also been 
studied in melanoma patients. Most notable of them are drugs targeting pro-
grammed death 1 (PD-1) receptor, another inhibitory regulator of T cells, and 
it’s ligand PD-L1 [10]. Examples of such drugs that have shown promising re-
sults in clinical trials on melanoma patients are nivolumab, lambrolizumab, 
and BMS-936559 [10-12]. 
Vemurafenib is a small-molecule inhibitor of V600 mutated BRAF kinase 
[13]. It was approved by FDA in 2011 for the treatment of patients with un-
resectable or metastatic melanoma with BRAF V600E mutation. In BRIM3 
phase III trial on previously-untreated patients with BRAF (V600) mutati-
on-positive metastatic melanoma both overall survival and progression free 
survival were significantly longer in patients treated with vemurafenib com-
pared to patients treated with dacarbazine [6,14]. In that trial 57% of patients 
responded to vemurafenib treatment. In 2013 another small-molecule inhi-
bitor of V600 mutated BRAF kinase, dabrafenib was approved by FDA for 
the treatment of treatment of BRAF V600E mutation-positive unresectable 
or metastatic melanoma. The approval was based on improved progression-
free survival shown in a phase III trial comparing dabrafenib to dacarbazine 
[15]. In that trial 50% of patients responded to dabrafenib treatment [15].  In 
addition to other side effects, a significant proportion of patients treated with 
these BRAF inhibitors have developed cutaneous squamous-cell carcinomas 
(SCC) and keratoacanthomas [6,15]. That can be explained by the mechanism 
of paradoxical activation of RAS-RAF-MEK-ERK signaling pathway in cells 
with non-mutated BRAF by vemurafenib and dabrafenib [16]. A limitation of 
these BRAF targeted drugs is durability of response with median duration 
of response in different clinical trials being approximately 6 months and gre-
at majority of patients eventually progressing within 1 year [6,15]. Different 
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resistance mechanisms that can account for that have been described, some 
of them involving reactivation of mitogen activated protein kinase (MAPK) 
pathway [17,18]. Potential strategy of overcoming MAPK pathway reactiva-
tion resistance to BRAF inhibitors is MAPK pathway blockade downstream 
of BRAF. An example of such drug is a mitogen-activated protein kinase ki-
nase (MEK) inhibitor, trametinib. Based on positive results of clinical trials 
trametinib was approved by FDA for the treatment of BRAF V600E or V600K 
mutation-positive unresectable or metastatic melanoma in 2013 as a single 
agent and in 2014 in combination with dabrafenib [19,20]. 
Drugs targeting other molecules and signaling pathways have also been 
studied in melanoma patients, like imatinib in melanoma patients with mu-
tated KIT, drugs targeting vascular endothelial growth factor (VEGF), and 
drugs targeting PI3K-AKT-mTOR pathway [21-23].
BRAF FUNCTION AND BRAF MUTATIONS IN MELANOMA 
Vemurafenib and dabrafenib are selectively targeting mutated and ac-
tivated form of BRAF protein that is coded by BRAF gene [13,24]. BRAF is, 
together with ARAF and CRAF (RAF1), a member of RAF kinase family of 
serine/threonine protein kinases that are involved in RAS-RAF-MEK-ERK si-
gnaling pathway [25]. This signaling pathway is activated when an extracel-
lular growth factor binds to a membrane-bound receptor with tyrosine kina-
se activity. Activation of different growth factor receptors leads to activation 
of RAS protein. RAS is a guanosine nucleotide-binding protein (G protein) 
that is critically involved in at least two different signaling pathways in addi-
tion to RAS-RAF-MEK-ERK pathway. In RAS-RAF-MEK-ERK pathway RAS 
activates RAF kinase, RAF phosphorylates and activates MEK and MEK 
phosphorylates and activates ERK mitogen activated protein kinases. ERK 
phosphorylates and activates different proteins: transcription factors that re-
gulate gene transcription in the nucleus, and cytoplasmic proteins that regu-
late protein translation and other processes. In that way RAS-RAF-MEK-ERK 
pathway plays a central role in cellular proliferation, growth, differentiation 
and some other processes. This signaling pathway is often disrupted in can-
cer [25]. Due to activating mutations in genes coding for RAS and RAF and 
some other mechanisms, signaling trough this pathway is constitutive, un-
regulated and increased leading to uncontrolled cellular proliferation which 
is a hallmark of cancer [25,26]. 
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Mutations in BRAF gene were found in different types of cancer, with 
high frequency in hairy cell leukemia (≈100%), melanomas (≈50%), papillary 
thyroid cancers (40-45%), colorectal cancers (8-15%), and ovarian cancers [26-
30]. The most frequent BRAF mutation in different cancers is an amino acid 
substitution from a valine to a glutamic acid at position 600 in BRAF, known 
as V600E mutation. V600E mutation represents 80-90% BRAF mutations in 
melanomas [26,30,31]. Among remainder of BRAF mutations in melanomas 
the most frequent are other amino acid substitutions at the same position, 
V600K (found in up to 20% melanoma patients with BRAF mutations), V600D, 
and V600R [27,30,31]. BRAF mutations were more frequently found in youn-
ger patients and patients without chronic sun damage of the surrounding 
skin [27,32-35]. It was shown that presence of BRAF mutations is associated 
with worse prognosis in patients with metastatic melanoma not treated with 
BRAF-directed therapy [27]. 
TESTING FOR BRAF MUTATIONS 
Testing for BRAF mutations is necessary before deciding about vemurafe-
nib, dabrafenib, and trametinib therapy. All these drugs have shown activity 
and have been approved only for patients with melanoma that has V600 mu-
tated BRAF. Furthermore, due to paradoxical activation of RAS-RAF-MEK-
ERK signaling pathway in cells with non-mutated BRAF, vemurafenib and 
dabrafenib could promote cancer growth in patients with BRAF V600 non-
mutated melanoma [16].
Different methods can be used to test for BRAF mutations: Sanger sequ-
encing, pyrosequencing, mutation-specific real-time PCR, high resolution 
melting analysis, immunohistochemistry with VE1 antibody specific for 
V600E mutated BRAF, mismatch ligation assay, and others. These methods 
differ regarding sensitivity, specificity, cost, time and expertise required, and 
other parameters [36-38]. In the USA vemurafenib was approved by FDA for 
patients with BRAF mutations as detected by cobas® 4800 BRAF V600 Mu-
tation Test (Roche Molecular Systems Inc.) as a companion diagnostic test, 
while dabrafenib and trametinib were approved for patients with BRAF mu-
tations as detected by THxID™ BRAF Kit (bioMérieux, Inc.) as a companion 
diagnostic test. In the approval of these drugs in the European Union by 
the European Medicines Agency (EMEA) no companion diagnostic test was 
prescribed. The cobas test has shown very high specificity for BRAF V600 
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mutations (<1% false-positives), high sensitivity of >95% for BRAF V600E mu-
tation, and capability to reliably detect BRAF V600E mutations present in as 
little as 5% of alleles present in a sample [39]. For comparison Sanger sequen-
cing can reliably detect mutations if at least 20% of alleles present in a sample 
are mutant. The cobas method can detect also V600K and V600D mutations, 
but with lower sensitivity and limit for detection and it cannot distinguish 
between different mutations [39]. This is a potential disadvantage of that 
method because although vemurafenib was approved only for patients with 
V600E mutation, it was shown that melanoma patients with V600K mutation 
could also benefit from vemurafenib treatment (14,40).
BRAF mutations can be detected in fresh and frozen tissue samples but 
most often they are detected in paraffin-embedded tissue samples which are 
often only samples available. Parameters that could increase BRAF mutation 
detection failure rate are the age of samples, poor fixation of samples and 
high level of pigmentation. Another important parameter is percentage of 
cancer cells in the sample which should be high for BRAF mutation analysis 
to be reliable and representative. However, it was shown that cobas method 
has very low failure rate for BRAF mutation detection [39,41].
BRAF mutation testing is usually performed on patients with metastatic 
or unresectable melanoma who are candidates for therapy with vemurafe-
nib, dabrafenib or trametinib. However, there are some valid arguments in 
favor of testing all patients with high-risk melanoma (American Joint Com-
mittee on Cancer stage IIb or higher) or even all patients upon diagnosis 
of melanoma [42]. When only patients who are candidates for therapy are 
tested, it is possible that time necessary to retrieve archived samples would 
delay initiation of therapy and thus decrease its potential benefit. It is also 
possible that only available archived samples from a patient would be old 
samples from initial biopsy what could increase BRAF mutation detection 
failure probability.  
One finding that limits clinical value of BRAF mutation detection is in-
tra-tumor and inter-tumor heterogeneity regarding the presence of BRAF 
mutations in a patient. It was shown that different regions within the same 
melanoma lesion can differ regarding the presence of BRAF mutations [43]. 
The results regarding the inter-tumor heterogeneity are conflicting. Seve-
ral studies have shown relatively high discordance but other studies have 
shown high concordance between different melanoma lesions (primary and 
different metastases) in the same patients regarding the BRAF mutation sta-
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tus [31,44-46]. Therefore, further studies are needed before making definitive 
conclusions regarding intra-patient BRAF mutation heterogeneity and its cli-
nical consequences. 
PREDICTIVE MARKERS FOR IPILIMUMAB THERAPY 
Because of relatively low response-rate but durable and clinically signi-
ficant response in patients responding to vemurafenib therapy, reliable pre-
dictive markers for vemurafenib would significantly improve management 
of patients with melanoma. However, in spite of different such potential mar-
kers being studied, none of them has shown the results that would justify its 
routine analysis. Markers that have shown promising results are increase in 
absolute lymphocyte count during treatment, presence of antibodies specific 
for NY-ESO1 antigen in serum, and baseline serum lactate dehydrogenase 
[47-49].  
CONCLUSION
Analysis of BRAF mutations in melanoma patients prior to vemurafenib, 
dabrafenib, and trametinib therapy is one of a few examples of molecular 
predictive markers related to personalized cancer therapy that has become 
standard routine clinical practice. However, there are still controversies and 
opened questions regarding the optimal protocol for routine BRAF mutation 
testing in melanoma patients. Probably the most pertinent issue is intra-pa-
tient heterogeneity regarding the BRAF mutations. Also, there are different 
views on the best method for BRAF mutation detection and which patients 
to test. There would be a great clinical benefit from other types of molecular 
markers for personalized approach to patients with melanoma, like predicti-
ve markers for ipilimumab therapy or markers to predict resistance to vemu-
rafenib therapy. No such marker has so far justified its routine analysis but 
several have shown promising results.
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Sažetak
Molekulski biljezi za personalizirani pristup bolesnicima s melanomom
2011. godina je bila prekretnica u liječenju bolesnika s melanomom budući da su te 
godine odobrena dva nova lijeka, vemurafenib i ipilimumab, koji su pokazali učinak na 
produženo preživljenje bolesnika s metastatskim melanomom. Vemurafenib je odobren 
za liječenje samo onih bolesnika koji imaju aktivirajuće mutacije u genu BRAF. Tako 
je detekcija aktivirajućih mutacija u genu BRAF, koje se mogu naći u ≈50% bolesnika 
s melanomom, postala standardni dio rutinskog protokola liječenja bolesnika s meta-
statskim melanomom. U ovom se radu raspravljaju metode i protokoli detekcije BRAF 
mutacija kao primjer molekulskog biljega za personalizirani pristup bolesnicima s me-
lanomom, s naglaskom na one aspekte koji su još predmet rasprava i kontroverzi. Osim 
mutacija u genu BRAF, u radu se ukratko raspravljaju i neki drugi molekulski biljezi za 
personalizirani pristup liječenju bolesnika s melanomom, kao prediktivni biljezi za lije-
čenje ipilimumabom, koji se još ne određuju rutinski.
Ključne riječi: melanom; BRAF mutacije; vemurafenib; ipilimumab; prediktivni bi-
ljezi; personalizirana medicina.
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